Search | IOVS | ARVO Journals

View

Showing 1 – 4 of 4

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (Phase 3)

Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1229. doi:

ARVO Annual Meeting Abstract July 2018

IOP lowering effect of omidenepag isopropyl in latanoprost non-/low-responder subjects with primary open-angle glaucoma or ocular hypertension: the FUJI study

Auli M Ropo; Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1233. doi:

ARVO Annual Meeting Abstract July 2018

A Phase 3 trial comparing omidenepag isopropyl 0.002% with latanoprost 0.005% in primary open-angle glaucoma and ocular hypertension: the AYAME study

Fenghe Lu; Makoto Aihara; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata; Naveed K Shams

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1235. doi:

ARVO Annual Meeting Abstract June 2017

Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Makoto Aihara; Fenghe Lu; Hisashi Kawata; Yuki Tanaka; Kenzo Yamamura; Ryo Iwamura; Kenji Yoneda; Noriko Odani; Naveed Shams

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2104. doi:

Advertisement